在性结肠炎中,Sishen药片通过miR-505-3p介导的E-cadherin下调抑制炎性树突细胞分化
Jiaqi Huang1, Youbao Zhong2, Nian Cheng1
1Department of Postgraduate, Jiangxi University of Chinese Medicine, Nanchang 330004, Jiangxi Province, China.
Phytomedicine : international journal of phytotherapy and phytopharmacology
|September 29, 2024
概括
西申药丸 (SSP) 通过抑制炎性树突细胞 (DC) 分化,有效治疗性结肠炎 (UC). 主要成分埃沃迪胺降低了miR-505-3p的调节,为UC提供了一种新的治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 是一种自身免疫性疾病,复发率高,治疗选择有限.
- 针对树突细胞 (DCs) 的炎症分化是UC的潜在治疗策略.
- 中国草药配方Sishen Pills (SSP) 显示出对UC的保护作用,但其机制尚不清楚.
研究的目的:
- 在小鼠中研究SSP对UC的保护作用.
- 阐明SSP涉及DC调节的机制,并确定关键活性成分.
- 通过转录组学,网络药理学以及体内/体外实验来验证发现.
主要方法:
- 用SSP治疗诱导UC小鼠模型;通过临床和病理标记评估有效性.
- 利用LC-MS/MS和网络药理学来识别SSP中的关键活性成分.
- 采用了转录基因测序,ELISA,流细胞计,RT-PCR和西式涂抹来分析DC功能和分子机制.
- 在体外使用骨髓衍生的树突细胞 (BMDCs) 和体内使用关键成分再验证的验证结果.
主要成果:
- SSP治疗缓解了UC症状和结肠损伤,降低了炎症性细胞因子 (IL-6,IL-1β,TNF-α) 水平和DC激活.
- 网络药理学确定了evodiaamine,isobavachalcone,curcumin和engenol作为潜在的关键化合物.
- 通过降低miR-505-3p和E-cadherin表达的调节,SSP抑制了BMDCs的炎症分化;埃沃胺被证实是关键活性成分.
- 击败miR-505-3p消除了SSP对BMDCs的治疗作用,证实了它的关键作用.
结论:
- 通过降低miR-505-3p的调节,SSP通过抑制炎症DC分化来预防UC.
- 埃沃胺被确定为SSP的关键活性成分,负责这种治疗效果.
- 这项研究提供了SSP对UC治疗的机制性理解,并突出了evodiaamine作为潜在的治疗剂.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
128
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
128
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
148
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
148